The U.S. Food and Drug Administration announced a program on Nov. 17 that gives eligible drugmakers more of the material behind an FDA decision. A company can request an assessment package with limited redactions and give it to another country's regulator as part of a marketing application. The FDA says the material can reduce duplicated review work. It does not grant permission to sell the product abroad.
The program started Oct. 30 with a tentative approval for a lenacapavir application under the President's Emergency Plan for AIDS Relief, known as PEPFAR. The tentative decision was not final U.S. marketing approval for that application. For now, eligibility is limited to tentative PEPFAR approvals and excludes products submitted through abbreviated new drug applications.
To receive a package, a company must apply within 10 calendar days after approval and confirm that a regulator outside the United States will receive it in support of a marketing application. Requests for other uses go through the ordinary public records process.
The FDA plans to add applications for novel drugs and biologics in January 2027. It also plans a separate route in early 2027 to speed up file requests for drugs and biologics that already have U.S. approval or a license.



